

Marketing Authorization

of Pharmaceutical Products with Special Reference to Multisource (Generic) Products

A manual for National Medicines Regulatory Authorities (NMRAs)

Marketing Authorization

of Pharmaceutical Products with Special Reference to Multisource (Generic) Products

A manual for National Medicines Regulatory Authorities (NMRAs)

WHO Library Cataloguing-in-Publication Data

Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for National Medicines Regulatory Authorities (NMRAs) – 2nd ed.

1.Legislation, Drug. 2.Pharmaceutical preparations - supply and distribution. 3.Drugs, Generic - supply and distribution. 4.Manuals. I.World Health Organization.

ISBN 978 92 4 150145 3

(NLM classification: QV 33)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design and Layout: paprika-annecy.com
Printed in Spain

CONTENTS

Preface	4
1. Introduction	6
2. Provisions and prerequisites for regulatory control	7
2.1 Political will and commitment	7
2.2 Legislation	7
2.3 Definition of responsibilities	7
2.4 Resources for the marketing authorization function	8
2.4.1 Staff	8
2.4.2 Premises	8
2.4.3 Archiving	8
2.4.4 Computers	8
2.5 Fees and cost recovery	9
2.6 Inventory of existing products on the market	10
2.7 Structure of the pharmaceutical market	10
2.7.1 Public health need	10
2.7.2 Number of interchangeable products	11
2.7.3 Price	11
2.8 Special access schemes	11
2.9 Postmarketing activities	12
2.10 Intellectual property	12
3. Good Regulatory Practice (GRP)	12
3.1 Definition of mission, vision and functions	13
3.2 Accountability	13
3.3 Transparency	14
3.4 Equity	15
3.5 Appeals and complaints	15
3.6 Personnel	16
3.6.1 Skills	16
3.6.2 Numbers	16
3.6.3 A code of conduct for officials	16
3.6.4 Training and ongoing professional updates	16
3.6.5 Public advertising of vacancies	16
3.6.6 Access to sources of information	16
3.6.7 A regulatory 'culture'	17
4. Organization, management and operational aspects	19
4.1 Policies	19
4.2 Administrative procedures	19
4.3 Timeframes for processing of applications	19
4.4 Expert advisory body	19
4.5 Risk management	20
4.5.1 Defining risk	21
4.5.2 Allocating resources according to risk	21

4.5.3	Risk and flexibility.....	22
4.5.4	Ongoing review of risk management practices.....	22
4.5.5	Variations to pharmaceutical aspects of registered products which may be made without prior approval, subject to conditions.....	22
4.6	Guidelines for applicants.....	22
4.7	Model application form for multisource products.....	23
4.8	Communication among departments within the NMRA.....	23
4.8.1	Relationship of evaluators with GMP inspectors.....	23
4.8.2	Relationship of evaluators with the quality control laboratories.....	24
4.8.3	Functional relationship of the evaluators with the expert advisory body.....	24
4.9	Relationship of evaluators with the pharmaceutical industry and confidentiality of data.....	25
4.9.1	General.....	25
4.9.2	Confidentiality of data.....	25
4.9.3	Progress of applications.....	25
4.10	Meetings with applicants.....	26
4.11	Collaboration with other NMRAs.....	26
4.12	Collaboration with WHO.....	27
4.13	Use of external experts as evaluators.....	27
4.14	Publication of marketing authorization decisions.....	28
5.	Review of applications for marketing authorization of multisource (generic) pharmaceutical products	29
5.1	Applicability.....	29
5.2	Initial decisions on options for premarket evaluation.....	29
5.2.1	Preparing an evaluation report.....	30
5.2.2	Relying on an evaluation report prepared by another national authority.....	30
5.2.3	Relying on a decision made by another national authority.....	30
5.3	Evaluation of data on quality.....	31
5.3.1	Domestically manufactured products.....	31
5.3.2	Imported products.....	31
5.3.3	Sampling and GMP inspections.....	32
5.4	Quality of starting materials.....	34
5.5	Container labelling.....	34
5.6	Toxicological, pharmacological and clinical data.....	34
5.7	Product Information.....	35
5.8	Interchangeability.....	35
5.9	The acceptability of data.....	36
5.9.1	Flexibility.....	36
5.9.2	Principles for determining whether data from the scientific literature are acceptable.....	36
6.	Issue of written marketing authorization.....	37
7.	Variations.....	37
8.	Periodic reviews.....	38
9.	Suspension and revocation of marketing authorization.....	39
	Glossary.....	40
	Abbreviations.....	45

Annexes	46
Annex 1	WHO guidelines and standards..... 46
Annex 2	Model documentation..... 51
Annex 3	Detailed advice to evaluators..... 75
Checklists	96
Checklist 1	Deciding the acceptability of an application for a marketing authorization 96
Checklist 2	Deciding the acceptability of an application for a periodic review..... 97
Checklist 3	Evaluating an application for a marketing authorization or periodic review..... 99
Checklist 4	Evaluating an application for a variation..... 101
Checklist 5	Evaluating a WHO-type certificate of pharmaceutical product..... 104
Checklist 6	Evaluating product information (and any patient information and/or package inserts)....106
Checklist 7	Evaluating interchangeability 107
Tables.....	109
Table 1	Guidelines to consider during an evaluation 109
Table 2	Reasons for seeking the information in the model application form..... 109
Table 3	Differences between (1) processing an application to vary and (2) processing an application for marketing authorization or periodic review 117
Table 4	Notes concerning possible consequences of differences between the product that is the subject of the application, and the product that is the subject of the WHO-type certificate..... 117
Table 5	International guidelines relating to the information on & validation of manufacture of the finished product that should be supplied with an application for marketing authorization... 119
Model letters	121
Model letter 1	Asking questions during the acceptance stage..... 121
Model letter 2	Accepting an application for Marketing Authorization 122
Model letter 3	Asking questions during the evaluation stage..... 123
Model letter 4	Approving a marketing authorization..... 124
Model letter 5	Renewal of Marketing Authorization following a Periodic Review 128
Model letter 6	Approval of a variation 132
Model letter 7	Rejection of an application 134
Model letter 8	Variation not notified/approved 135
References	136
Charts.....	
Chart 1	Decision tree for marketing authorization of domestic products..... 33
Chart 2	Decision tree for marketing authorization of imported products 33
Chart 3	Processing an application for a marketing authorization or a periodic review 76
Chart 4	Options when the WHO-type certificate is unsatisfactory..... 79
Chart 5	Options for WHO-type certificates when there is more than one site of manufacture..... 80
Chart 6	Deciding a comparator pharmaceutical product..... 81
Chart 7	Processing an application for a variation..... 82

PREFACE

In 1999, WHO published a manual entitled Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) products - a Manual for a Drug Regulatory Authority. After an initial distribution of two thousand copies to the Regulatory Authorities of WHO member countries, more than three thousand additional copies were printed and distributed in response to requests. Feedback was received from many who have used the manual in their assessment work or in training courses. The manual became known as the Blue Book and has been used as reference document when the WHO Prequalification of Medicines Programme started in 2001.

This is the second edition of the Blue Book. In developing this new edition, many practical suggestions made by regulatory officials were taken into account and incorporated as far as possible. Now included are a series of documents that will be of practical assistance to regulatory authorities, including checklists, flow charts, model evaluation reports and model correspondence. Relevant WHO guidelines (such as those concerning stability and bio-equivalence testing) are referenced in the text but are no longer attached for these reasons:

- With the additional material to be incorporated in this edition, the Blue Book could have become long and cumbersome;
- Updated versions of guidelines may become available before a new version of the Blue Book is produced;
- All of the relevant guidelines are available via the WHO website¹.

Conference on Harmonization (ICH), to date ICH has focussed on new chemical and biological substances, and new dosage forms that contain new substances. However regulatory requirements for multisource (generic) medicines are somewhat different, and these are the main focus of the Blue Book.

Like the first edition, the new Blue Book offers regulatory authorities a number of options for the administration of medicines regulation. In the case of pre-marketing evaluation, the options can be grouped into three broad categories:

- No pre-marketing evaluation;
- Verification of regulatory status in other countries;
- Full assessment of application data.

The first option puts patients and public health at risk and is obviously not acceptable. For most countries the most realistic approach is a combination of the other two options. This requires setting up a system that will permit:

- Identification of reference countries or authorities whose regulatory decisions are considered acceptable or recognizable; and
- Conducting assessments of applications on the basis of a number of criteria established within the limits imposed, on one side, by a reasonable certainty of filtering out substandard, unsafe products and, on the other side, by the available human and material resources.

This manual is based on the above considerations and aims at providing technical advice to countries

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28690

